Pasithea Therapeutics Corp.(KTTA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

KTTA Pasithea Therapeutics Corp.

未开盘 05-01 16:00:00 EDT

0.8410

+0.1463

+21.06%

盘后0.8330

-0.0080-0.95%

19:58 EDT

最高0.8601	最低0.6900	成交量168.21万
今开0.7150	昨收0.6947	日振幅24.49%
总市值2,097万	流通市值1,409万	总股本2,494万
成交额126.30万	换手率10.04%	流通股本1,675万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"KTTA","market":"US","secType":"STK","nameCN":"Pasithea Therapeutics Corp.","latestPrice":0.841,"timestamp":1777665600000,"preClose":0.6947,"halted":0,"volume":1682097,"hourTrading":{"tag":"盘后","latestPrice":0.833,"preClose":0.841,"latestTime":"19:58 EDT","volume":78990,"amount":67762.973571,"timestamp":1777679937614,"change":-0.008,"changeRate":-0.009512,"amplitude":0.082996},"delay":0,"changeRate":0.21059450122354972,"floatShares":16753400,"shares":24939899,"eps":-2.91,"marketStatus":"未开盘","change":0.1463,"latestTime":"05-01 16:00:00 EDT","open":0.715,"high":0.8601,"low":0.69,"amount":1262972.7593331,"amplitude":0.244854,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.91,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1777881600000},"marketStatusCode":0,"adr":0,"listingDate":1628654400000,"exchange":"NASDAQ","adjPreClose":0.6947,"postHourTrading":{"tag":"盘后","latestPrice":0.833,"preClose":0.841,"latestTime":"19:58 EDT","volume":78990,"amount":67762.973571,"timestamp":1777679937614,"change":-0.008,"changeRate":-0.009512,"amplitude":0.082996},"volumeRatio":8.451321423972741},"requestUrl":"/m/hq/s/KTTA","defaultTab":"news","newsList":[{"id":"1102952162","title":"Pasithea Therapeutics获FDA授予罕见儿科疾病认定 RPDD 予PAS-004用于治疗1型神经纤维瘤病","url":"https://stock-news.laohu8.com/highlight/detail?id=1102952162","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102952162?lang=zh_cn&edition=full","pubTime":"2026-04-20 19:08","pubTimestamp":1776683330,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics Corp. 宣布，其研发药物PAS-004已获得美国食品药品监督管理局授予的罕见儿科疾病认定，该药物拟用于治疗1型神经纤维瘤病。这一认定标志着PAS-004在针对儿童罕见病治疗领域的研发进程中迈出了重要一步。获得RPDD资格意味着，若PAS-004后续获得新药上市批准，该公司将有资格获得一张优先审评券。1型神经纤维瘤病是一种遗传性神经系统疾病，主要表现为皮肤色素斑和神经纤维瘤的形成。PAS-004作为一种创新疗法，其研发进展为患者群体带来了新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KTTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145086968","title":"Pasithea Therapeutics获FDA授予快速通道资格，Pas-004有望治疗I型神经纤维瘤病相关丛状神经纤维瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=1145086968","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145086968?lang=zh_cn&edition=full","pubTime":"2026-04-01 19:04","pubTimestamp":1775041499,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics Corp.（以下简称\"Pasithea\"）宣布，其研发的药物Pas-004已获得美国食品药品监督管理局（FDA）授予的快速通道资格。该药物旨在治疗I型神经纤维瘤病（Nf1）相关的丛状神经纤维瘤（Pn），此类肿瘤可导致显著的发病率和严重健康问题。\n快速通道资格的授予将加速Pas-004的研发和审评进程，为患者提供更早获得创新疗法的可能。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KTTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613711380","title":"Pasithea Therapeutics Corp.盘中异动 早盘股价大涨7.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613711380","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613711380?lang=zh_cn&edition=full","pubTime":"2026-02-23 22:32","pubTimestamp":1771857144,"startTime":"0","endTime":"0","summary":"北京时间2026年02月23日22时32分，Pasithea Therapeutics Corp.股票出现波动，股价大幅拉升7.75%。截至发稿，该股报0.862美元/股，成交量6105股，换手率0.03%，振幅0.00%。Pasithea Therapeutics Corp.股票所在的生物技术行业中，整体跌幅为0.08%。其相关个股中，Arcellx, Inc.、Vanda Pharmaceuticals Inc.、传奇生物涨幅较大，Psyence Biomedical Ltd.、Cardio Diagnostics Holdings Inc.、Fortress Biotech, Inc.较为活跃，换手率分别为177.56%、38.78%、25.84%，振幅较大的相关个股有Psyence Biomedical Ltd.、Cardio Diagnostics Holdings Inc.、Camp4 Therapeutics Corporation，振幅分别为15.58%、11.46%、9.68%。Pasithea Therapeutics Corp.公司简介：Pasithea Therapeutics Corp是一家生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223223225a7163268&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223223225a7163268&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","KTTA","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101274106","title":"Form 4 | Pasithea Therapeutics Corp.董事 Lawrence Steinman 增持133,333股","url":"https://stock-news.laohu8.com/highlight/detail?id=1101274106","media":"老虎公告助手","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101274106?lang=zh_cn&edition=full","pubTime":"2025-12-01 22:10","pubTimestamp":1764598216,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics Corp. (股票代码: KTTA) 的董事 Lawrence Steinman 于2025年11月28日增持了133,333股普通股票，交易价格为每股0.75美元，交易完成后，Lawrence Steinman持有199,691股普通股票。高管及董事的增持通常被视为对公司前景的信心信号，可能会对公司股价产生积极影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Form 4 | Pasithea Therapeutics Corp.董事 Lawrence Steinman 增持133,333股","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2586228903","title":"Sutro Biopharma, Inc.盘中异动 临近收盘股价大涨5.23%报0.905美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2586228903","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586228903?lang=zh_cn&edition=full","pubTime":"2025-11-27 04:58","pubTimestamp":1764190719,"startTime":"0","endTime":"0","summary":"北京时间2025年11月27日04时58分，Sutro Biopharma, Inc.股票出现异动，股价快速上涨5.23%。截至发稿，该股报0.905美元/股，成交量47.4418万股，换手率0.56%，振幅8.45%。Sutro Biopharma, Inc.股票所在的生物技术行业中，整体涨幅为0.67%。Sutro Biopharma, Inc.公司简介：Sutro Biopharma Inc 一家临床阶段药物发现、开发和制造公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251127045840a7139f2f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251127045840a7139f2f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","KTTA","STRO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2586403261","title":"Novabay Pharmaceuticals, Inc.盘中异动 股价大涨5.30%报0.990美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2586403261","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586403261?lang=zh_cn&edition=full","pubTime":"2025-11-27 01:15","pubTimestamp":1764177340,"startTime":"0","endTime":"0","summary":"北京时间2025年11月27日01时15分，Novabay Pharmaceuticals, Inc.股票出现波动，股价急速拉升5.30%。截至发稿，该股报0.990美元/股，成交量8.6234万股，换手率0.07%，振幅6.91%。Novabay Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.31%。Novabay Pharmaceuticals, Inc.公司简介：NovaBay Pharmaceuticals Inc是一家生物制药公司，开发和销售科学创造和临床眼部护理,伤口护理和皮肤护理产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251127011541951c0944&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251127011541951c0944&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","NBY","KTTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2586267933","title":"Maia Biotechnology, Inc.盘中异动 早盘股价大涨5.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586267933","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586267933?lang=zh_cn&edition=full","pubTime":"2025-11-26 23:11","pubTimestamp":1764169894,"startTime":"0","endTime":"0","summary":"北京时间2025年11月26日23时11分，Maia Biotechnology, Inc.股票出现异动，股价大幅上涨5.16%。Maia Biotechnology, Inc.股票所在的生物技术行业中，整体涨幅为0.57%。其相关个股中，Pasithea Therapeutics Corp C/Wts 12/08/2026 、Pasithea Therapeutics Corp.、Lexaria Bioscience Corp C/Wts 14/01/2026 涨幅较大，Scisparc Ltd.、Pasithea Therapeutics Corp.、Kala Bio, Inc.较为活跃，换手率分别为2436.49%、430.58%、179.75%，振幅较大的相关个股有Pasithea Therapeutics Corp C/Wts 12/08/2026 、Pasithea Therapeutics Corp.、Lixte Biotechnology Holdings  Inc C/Wts 30/11/2025 ，振幅分别为272.65%、170.86%、49.76%。Maia Biotechnology, Inc.公司简介：MAIA Biotechnology Inc 是一家临床阶段的生物制药公司，致力于开发针对癌症的靶向免疫疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251126231134a7134195&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251126231134a7134195&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","MAIA","KTTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167809601","title":"Pasithea Therapeutics获得ALS协会100万美元资金，研究Pas-004在治疗ALS中的疗效、安全性和耐受性","url":"https://stock-news.laohu8.com/highlight/detail?id=1167809601","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167809601?lang=zh_cn&edition=full","pubTime":"2025-11-25 20:02","pubTimestamp":1764072154,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics获得ALS协会100万美元资金，用于研究Pas-004在治疗肌萎缩侧索硬化症（ALS）中的疗效、安全性和耐受性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","KTTAW","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2586124504","title":"Kala Bio, Inc.盘中异动 早盘急速上涨5.37%报0.653美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2586124504","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586124504?lang=zh_cn&edition=full","pubTime":"2025-11-24 23:10","pubTimestamp":1763997043,"startTime":"0","endTime":"0","summary":"北京时间2025年11月24日23时10分，Kala Bio, Inc.股票出现异动，股价快速上涨5.37%。截至发稿，该股报0.653美元/股，成交量2.593万股，换手率0.37%，振幅3.65%。Kala Bio, Inc.股票所在的生物技术行业中，整体涨幅为0.83%。其相关个股中，Enlivex Therapeutics Ltd.、Pasithea Therapeutics Corp C/Wts 12/08/2026 、Lixte Biotechnology Holdings  Inc C/Wts 30/11/2025 涨幅较大，Enlivex Therapeutics Ltd.、Pasithea Therapeutics Corp.、Osr Holdings, Inc.较为活跃，换手率分别为578.03%、445.40%、65.40%，振幅较大的相关个股有Enlivex Therapeutics Ltd.、Pasithea Therapeutics Corp.、Reviva Pharmaceuticals Holdings Inc C/Wts 25/12/2025，振幅分别为47.95%、39.27%、30.30%。Kala Bio, Inc.公司简介：Kala Bio Inc 是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124231043977cba1d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124231043977cba1d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4007","KALA","KTTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2586496674","title":"Xencor, Inc.盘中异动 早盘快速拉升5.04%报16.67美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2586496674","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586496674?lang=zh_cn&edition=full","pubTime":"2025-11-24 22:48","pubTimestamp":1763995695,"startTime":"0","endTime":"0","summary":"北京时间2025年11月24日22时48分，Xencor, Inc.股票出现异动，股价大幅上涨5.04%。截至发稿，该股报16.67美元/股，成交量7.1489万股，换手率0.10%，振幅4.06%。Xencor, Inc.股票所在的生物技术行业中，整体涨幅为0.65%。Xencor, Inc.公司简介：Xencor， Inc 是一家临床阶段的生物制药公司，专注于发现和开发工程抗体疗法，以治疗癌症和自身免疫性疾病患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124224815a4b75a4b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124224815a4b75a4b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KTTA","XNCR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2586978394","title":"Alps Group Inc盘中异动 早盘急速拉升6.78%报1.26美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2586978394","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586978394?lang=zh_cn&edition=full","pubTime":"2025-11-24 22:38","pubTimestamp":1763995094,"startTime":"0","endTime":"0","summary":"北京时间2025年11月24日22时38分，Alps Group Inc股票出现波动，股价快速上涨6.78%。截至发稿，该股报1.26美元/股，成交量19.2075万股，换手率0.12%，振幅7.63%。Alps Group Inc股票所在的生物技术行业中，整体涨幅为0.45%。Alps Group Inc公司简介：ALPS Group Inc是一家集生物技术研究、医疗和健康服务于一体的综合性平台，专注于预测性、精准性和预防性健康管理。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124223814977cad8d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124223814977cad8d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ALPS","BK4213","KTTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2586116444","title":"Seastar Medical Holding Corp C/Wts 28/10/2027 (To Pur Com)盘中异动 早盘急速拉升6.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586116444","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586116444?lang=zh_cn&edition=full","pubTime":"2025-11-24 22:36","pubTimestamp":1763994963,"startTime":"0","endTime":"0","summary":"北京时间2025年11月24日22时36分，Seastar Medical Holding Corp C/Wts 28/10/2027 股票出现波动，股价急速上涨6.12%。Seastar Medical Holding Corp C/Wts 28/10/2027 股票所在的生物技术行业中，整体涨幅为0.58%。其相关个股中，Pasithea Therapeutics Corp C/Wts 12/08/2026 、Enlivex Therapeutics Ltd.、Reviva Pharmaceuticals Holdings Inc C/Wts 25/12/2025涨幅较大，Enlivex Therapeutics Ltd.、Pasithea Therapeutics Corp.、Osr Holdings, Inc.较为活跃，换手率分别为415.90%、306.60%、40.71%，振幅较大的相关个股有Pasithea Therapeutics Corp.、Enlivex Therapeutics Ltd.、Bioatla, Inc.，振幅分别为30.35%、21.19%、16.60%。Seastar Medical Holding Corp C/Wts 28/10/2027 公司简介：SeaStar Medical Holding Corp 是一家医疗技术公司，开发专有解决方案，以减少过度炎症对重要器官的后果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124223603a4b754fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124223603a4b754fc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ICUCW","KTTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2586418212","title":"Atyr Pharma, Inc.盘中异动 股价大涨5.00%报0.698美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2586418212","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586418212?lang=zh_cn&edition=full","pubTime":"2025-11-24 22:33","pubTimestamp":1763994800,"startTime":"0","endTime":"0","summary":"北京时间2025年11月24日22时33分，Atyr Pharma, Inc.股票出现异动，股价大幅拉升5.00%。截至发稿，该股报0.698美元/股，成交量5.4894万股，换手率0.06%，振幅4.50%。Atyr Pharma, Inc.股票所在的生物技术行业中，整体涨幅为0.35%。Atyr Pharma, Inc.公司简介：aTyr Pharma Inc 是一家生物治疗公司，致力于通过其专有的 tRNA 合成酶平台发现和开发一流的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124223321977cabaf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124223321977cabaf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ATYR","KTTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2586176491","title":"Clearside Biomedical, Inc.股价重挫69.85% 市值跌299.87万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2586176491","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586176491?lang=zh_cn&edition=full","pubTime":"2025-11-24 22:31","pubTimestamp":1763994711,"startTime":"0","endTime":"0","summary":"北京时间2025年11月24日22时31分，Clearside Biomedical, Inc.股票出现异动，股价急速下跌69.85%。Clearside Biomedical, Inc.股票所在的生物技术行业中，整体涨幅为0.35%。Clearside Biomedical, Inc.公司简介：Clearside Biomedical Inc 是一家总部位于美国的临床生物制药公司，致力于开发通过脉络膜上腔或 SCS 治疗眼部致盲疾病的药物疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124223151a70e8a47&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124223151a70e8a47&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KTTA","BK4139","CLSDQ","CLSD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111694989","title":"Pasithea Therapeutics宣布在晚期癌症患者中完成Pas-004的第7组阶段I临床试验，取得积极的安全性、药代动力学（Pk）和药效动力学（Pd）数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1111694989","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111694989?lang=zh_cn&edition=full","pubTime":"2025-11-24 20:02","pubTimestamp":1763985763,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics宣布在晚期癌症患者中完成Pas-004的第7组阶段I临床试验，取得积极的安全性、药代动力学（Pk）和药效动力学（Pd）数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KTTA","KTTAW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134137576","title":"Pasithea Therapeutics Corp -第七组（37毫克胶囊）DLT期内未观察到与治疗相关的不良事件","url":"https://stock-news.laohu8.com/highlight/detail?id=1134137576","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134137576?lang=zh_cn&edition=full","pubTime":"2025-11-24 20:02","pubTimestamp":1763985761,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics Corp -第七组（37毫克胶囊）DLT期内未观察到与治疗相关的不良事件","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KTTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179978808","title":"Pasithea Therapeutics公布在成人NF1患者中进行的1/1B期试验中Pas-004片剂的积极药代动力学（Pk）数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1179978808","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179978808?lang=zh_cn&edition=full","pubTime":"2025-11-22 01:35","pubTimestamp":1763746513,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics公布在成人NF1患者中进行的1/1B期试验中Pas-004片剂的积极药代动力学（Pk）数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTAW","BK4139","KTTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122423961","title":"Pasithea Therapeutics发布积极的1期数据，包括部分缓解，显示Pas-004在晚期癌症研究中的单药临床活性和良好的安全性","url":"https://stock-news.laohu8.com/highlight/detail?id=1122423961","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122423961?lang=zh_cn&edition=full","pubTime":"2025-11-21 05:02","pubTimestamp":1763672533,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics发布积极的1期数据，包括部分缓解，显示Pas-004在晚期癌症研究中的单药临床活性和良好的安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KTTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122325511","title":"Pasithea Therapeutics Corp：Pas-004 的耐受性良好，所有相关不良事件均为1级或2级","url":"https://stock-news.laohu8.com/highlight/detail?id=1122325511","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122325511?lang=zh_cn&edition=full","pubTime":"2025-11-21 05:02","pubTimestamp":1763672530,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics Corp：Pas-004 的耐受性良好，所有相关不良事件均为1级或2级。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KTTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518205086","title":"Pasithea Therapeutics Corp.盘中异动 大幅下跌9.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518205086","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518205086?lang=zh_cn&edition=full","pubTime":"2025-03-11 01:39","pubTimestamp":1741628391,"startTime":"0","endTime":"0","summary":"北京时间2025年03月11日01时39分，Pasithea Therapeutics Corp.股票出现波动，股价急速下挫9.24%。截至发稿，该股报1.08美元/股，成交量7371股，换手率0.58%，振幅3.84%。Pasithea Therapeutics Corp.股票所在的生物技术行业中，整体涨幅为0.87%。其相关个股中，Aeon Biopharma, Inc.、Mineralys Therapeutics, Inc.、Checkpoint Therapeutics, Inc.涨幅较大，Aeon Biopharma, Inc.、Biodexa Pharmaceuticals Plc、Scisparc Ltd.较为活跃，换手率分别为5288.34%、3824.05%、989.31%，振幅较大的相关个股有Aeon Biopharma, Inc.、Protagenic Therapeutics Inc C/Wts 29/04/2026 、Biodexa Pharmaceuticals Plc，振幅分别为90.44%、88.14%、58.34%。Pasithea Therapeutics Corp.公司简介：Pasithea Therapeutics Corp 是一家生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031101395296406773&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031101395296406773&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","KTTA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pasithea.com","stockEarnings":[{"period":"1week","weight":0.2188},{"period":"1month","weight":0.1304},{"period":"3month","weight":-0.0232},{"period":"6month","weight":0.0336},{"period":"1year","weight":-0.4467},{"period":"ytd","weight":-0.3481}],"compareEarnings":[{"period":"1week","weight":0.0094},{"period":"1month","weight":0.0998},{"period":"3month","weight":0.0414},{"period":"6month","weight":0.0566},{"period":"1year","weight":0.2904},{"period":"ytd","weight":0.0568}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Pasithea Therapeutics Corp.于2020年5月12日在特拉华州注册成立。该公司是一家临床阶段的生物技术公司，专注于发现、研究和开发针对中枢神经系统疾病和其他疾病的创新疗法，包括RASopathies。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.182441},{"month":2,"riseRate":0.4,"avgChangeRate":-0.152614},{"month":3,"riseRate":0.4,"avgChangeRate":-0.0152},{"month":4,"riseRate":0.2,"avgChangeRate":0.004803},{"month":5,"riseRate":0.4,"avgChangeRate":-0.140236},{"month":6,"riseRate":0.5,"avgChangeRate":0.06208},{"month":7,"riseRate":1,"avgChangeRate":0.10295},{"month":8,"riseRate":0.5,"avgChangeRate":-0.003687},{"month":9,"riseRate":0.5,"avgChangeRate":-0.003936},{"month":10,"riseRate":0.2,"avgChangeRate":-0.132455},{"month":11,"riseRate":0.4,"avgChangeRate":0.147256},{"month":12,"riseRate":0.4,"avgChangeRate":-0.165941}],"exchange":"NASDAQ","name":"Pasithea Therapeutics Corp.","nameEN":"Pasithea Therapeutics Corp."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Pasithea Therapeutics Corp.(KTTA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Pasithea Therapeutics Corp.(KTTA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Pasithea Therapeutics Corp.,KTTA,Pasithea Therapeutics Corp.股票,Pasithea Therapeutics Corp.股票老虎,Pasithea Therapeutics Corp.股票老虎国际,Pasithea Therapeutics Corp.行情,Pasithea Therapeutics Corp.股票行情,Pasithea Therapeutics Corp.股价,Pasithea Therapeutics Corp.股市,Pasithea Therapeutics Corp.股票价格,Pasithea Therapeutics Corp.股票交易,Pasithea Therapeutics Corp.股票购买,Pasithea Therapeutics Corp.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Pasithea Therapeutics Corp.(KTTA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Pasithea Therapeutics Corp.(KTTA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}